New pill combo takes aim at Hard-to-Treat cancers

NCT ID NCT06077877

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental oral drug called GSK4524101, either alone or combined with another drug (niraparib), in adults with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and second, seeing if the combination shrinks tumors in people with a specific type of breast cancer. Only 42 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK4524101 (a DNA repair blocker) and niraparib (a PARP inhibitor)
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid tumors, especially those with BRCA-mutated breast cancer.
What could go wrong: This is a very early (Phase 1/2) and small trial (42 people). The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site

San Francisco, California, 94158, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

Dallas, Texas, 75230, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

Fairfax, Virginia, 22031, United States
GSK Investigational Site

Edmonton, Alberta, T6G 1Z2, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Panama City, Panama
GSK Investigational Site

Punta Pacifica Panama City Panama, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.